NYSEAMERICAN:VNRX - VolitionRX Stock Price, News & Analysis

$4.08
-0.15 (-3.55 %)
(As of 08/19/2019 04:00 PM ET)
Today's Range
$4.03
Now: $4.08
$4.22
50-Day Range N/A
52-Week Range
$1.67
Now: $4.08
$4.65
Volume58,817 shs
Average Volume100,490 shs
Market Capitalization$167.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$167.65 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.


VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) posted its quarterly earnings results on Monday, August, 12th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.01. View VolitionRX's Earnings History.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for VolitionRX.

What price target have analysts set for VNRX?

2 analysts have issued twelve-month price targets for VolitionRX's stock. Their predictions range from $5.00 to $6.00. On average, they expect VolitionRX's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 34.8% from the stock's current price. View Analyst Price Targets for VolitionRX.

What is the consensus analysts' recommendation for VolitionRX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

Media stories about VNRX stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VolitionRX earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for VolitionRX.

Are investors shorting VolitionRX?

VolitionRX saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 61,000 shares, an increase of 11.1% from the June 30th total of 54,900 shares. Based on an average trading volume of 104,200 shares, the short-interest ratio is presently 0.6 days. Currently, 0.3% of the company's stock are short sold. View VolitionRX's Current Options Chain.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the folowing people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by a number of of institutional and retail investors. Top institutional investors include Morgan Stanley (0.25%), Ladenburg Thalmann Financial Services Inc. (0.08%) and Leisure Capital Management (0.04%). Company insiders that own VolitionRX stock include Cameron John Reynolds, David Cecil Vanston, Guy Archibald Innes and Martin Charles Faulkes. View Institutional Ownership Trends for VolitionRX.

Which major investors are selling VolitionRX stock?

VNRX stock was sold by a variety of institutional investors in the last quarter, including Leisure Capital Management. View Insider Buying and Selling for VolitionRX.

Which major investors are buying VolitionRX stock?

VNRX stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley and Ladenburg Thalmann Financial Services Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, David Cecil Vanston, Guy Archibald Innes and Martin Charles Faulkes. View Insider Buying and Selling for VolitionRX.

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $4.08.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $167.65 million. VolitionRX employs 44 workers across the globe.View Additional Information About VolitionRX.

What is VolitionRX's official website?

The official website for VolitionRX is http://www.volitionrx.com/.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.


MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  302
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel